MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Waters Corporation Gross Profit 2011-2026 | WAT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Waters Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 1.4 B | 1.43 B | 1.36 B | 1.28 B | 1.2 B | 1.16 B | 1.12 B | 1.11 B | 1.12 B | 990 M | 904 M | 914 M | 842 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 842 M | 1.14 B |
Quarterly Gross Profit Waters Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 316 M | 274 M | 349 M | 294 M | 286 M | 271 M | 351 M | 291 M | 280 M | 243 M | 336 M | 266 M | 263 M | 256 M | 313 M | 267 M | 272 M | 253 M | 317 M | 274 M | 272 M | 258 M | 238 M | 236 M | 222 M | 221 M | 219 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 351 M | 219 M | 275 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 17.26 | -7.0 % | $ 181 M |  China |
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
400 K | $ 1.34 | -17.79 % | $ 1.78 M |  USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 15.78 | -2.53 % | $ 477 M | USA |
 |
Agilent Technologies
A
|
2.84 B | $ 112.09 | -1.02 % | $ 34.1 B | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 19.05 | 0.9 % | $ 552 M | USA |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
2.86 B | $ 139.97 | -2.28 % | $ 22.3 B | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
24.1 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 19.83 | -3.22 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 94.74 | -2.0 % | $ 6.39 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
246 M | $ 419.82 | 0.16 % | $ 12.1 B | USA |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 043.89 | 0.19 % | $ 21.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
577 M | $ 3.6 | -0.69 % | $ 333 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
NeoGenomics
NEO
|
314 M | $ 8.28 | -0.96 % | $ 1.06 B | USA |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 18.46 | -2.48 % | $ 413 M | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 157.18 | -1.33 % | $ 7.79 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
Natera
NTRA
|
127 M | $ 186.22 | -5.43 % | $ 18.3 B | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 25.27 | -0.94 % | $ 24 B |  Niderland |
 |
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
144 M | $ 92.95 | -5.79 % | $ 11.7 B | USA |
 |
Senseonics Holdings
SENS
|
15.8 M | $ 5.73 | -1.55 % | $ 239 M | USA |
 |
Personalis
PSNL
|
22.1 M | $ 6.47 | -3.64 % | $ 577 M | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 117.95 | 0.73 % | $ 9.73 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
-58.5 K | $ 52.99 | -0.01 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
6.96 M | $ 49.3 | -6.89 % | $ 2.95 B | USA |
 |
Biomerica
BMRA
|
498 K | $ 2.31 | -4.04 % | $ 5.31 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 251.18 | -1.12 % | $ 20.9 B | USA |
 |
Thermo Fisher Scientific
TMO
|
11.3 B | $ 439.31 | -1.97 % | $ 166 B | USA |
 |
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.57 | -1.49 % | $ 205 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
421 M | $ 8.27 | -1.9 % | $ 1.79 B | USA |